Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Progressive Multiple Sclerosis
NCT03523858Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2018
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 24
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoints: No Evidence of Progression at 192 weeks and No evidence of progression and no active disease at 192 weeks. Started May 2018; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03523858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523858.